GF Fund Management CO. LTD. purchased a new stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 7,835 shares of the biotechnology company's stock, valued at approximately $4,656,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Fourth Dimension Wealth LLC acquired a new stake in shares of Axon Enterprise during the fourth quarter worth about $30,000. New Wave Wealth Advisors LLC purchased a new stake in Axon Enterprise in the fourth quarter valued at $40,000. Y.D. More Investments Ltd acquired a new stake in Axon Enterprise during the 4th quarter worth about $45,000. Elequin Capital LP purchased a new position in shares of Axon Enterprise during the 4th quarter valued at about $46,000. Finally, Stonebridge Financial Group LLC acquired a new position in shares of Axon Enterprise in the 4th quarter valued at about $53,000. Hedge funds and other institutional investors own 79.08% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the company. Craig Hallum cut Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. The Goldman Sachs Group lifted their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Needham & Company LLC increased their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. JMP Securities restated an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Finally, Northcoast Research downgraded shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $652.73.
Read Our Latest Stock Report on AXON
Insider Transactions at Axon Enterprise
In other news, CFO Brittany Bagley sold 3,400 shares of the company's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $700.00, for a total transaction of $2,380,000.00. Following the completion of the sale, the chief financial officer now owns 131,833 shares of the company's stock, valued at $92,283,100. This represents a 2.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the transaction, the chief executive officer now directly owns 3,063,982 shares in the company, valued at approximately $1,657,583,622.18. This represents a 0.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 34,969 shares of company stock valued at $23,127,314 over the last ninety days. Insiders own 5.70% of the company's stock.
Axon Enterprise Price Performance
Shares of NASDAQ AXON traded up $3.71 during trading on Friday, hitting $734.00. The company had a trading volume of 213,044 shares, compared to its average volume of 731,861. The firm has a market capitalization of $57.14 billion, a price-to-earnings ratio of 189.66, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24. The stock has a fifty day simple moving average of $617.24 and a two-hundred day simple moving average of $609.47. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a fifty-two week low of $273.52 and a fifty-two week high of $755.05.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The firm had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. During the same period last year, the company posted $1.15 EPS. Axon Enterprise's quarterly revenue was up 31.3% compared to the same quarter last year. On average, research analysts expect that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.
About Axon Enterprise
(
Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More

Before you consider Axon Enterprise, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.
While Axon Enterprise currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.